Evidence map›Paper›PMID 24234652›Full record

ArticleHuman molecular genetics2014

LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner.

Bisei Ohkawara, Macarena Cabrera-Serrano, Tomohiko Nakata, Margherita Milone, Nobuyuki Asai, Kenyu Ito, Mikako Ito, Akio Masuda, Yasutomo Ito, Andrew G Engel and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Congenital myasthenic syndromes.Orphanet journal of rare diseases · 2019
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Muscles (Basel, Switzerland) · 2026
    Review
  6. Article
  7. The Neuromuscular Junction: A Shared Vulnerability in Aging and Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Structural insights into the assembly of the agrin/LRP4/MuSK signaling complex.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  16. Article
  17. Review
  18. Rare Variants inBiology · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Bisei OhkawaraDivision of Neurogenetics, Center for Neurological Diseases and Cancer and.
Macarena Cabrera-Serrano
Tomohiko Nakata
Margherita Milone
Nobuyuki Asai
Kenyu Ito
Mikako Ito
Akio Masuda
Yasutomo Ito
Andrew G Engel
Kinji Ohno
Mayo Clinic in Arizona · USNagoya University · JP

Funding

ELECTRON MICROSCOPY OF MYOPATHIESR01NS006277 · NINDS · MAYO CLINIC ROCHESTER · PI ENGEL, ANDREW GEORGE · 1985 to 2015
$7.8M
Congenital Myasthenic SyndromesR56NS006277 · NINDS · MAYO CLINIC ROCHESTER · PI ENGEL, ANDREW GEORGE, SELCEN, DUYGU · 2017 to 2017
$539k
NINDS NIH HHS NS6277NINDS NIH HHS R01 NS006277NINDS NIH HHS R56 NS006277
6 · The paper itself

Abstract

Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Using Sanger and exome sequencing in a CMS patient, we identified two heteroallelic mutations, p.Glu1233Lys and p.Arg1277His, in LRP4 coding for the postsynaptic low-density lipoprotein receptor-related protein 4. LRP4, expressed on the surface of the postsynaptic membrane of the neuromuscular junction, is a receptor for neurally secreted agrin, and LRP4 bound by agrin activates MuSK. Activated MuSK in concert with Dok-7 stimulates rapsyn to concentrate and anchor AChR on the postsynaptic membrane and interacts with other proteins implicated in the assembly and maintenance of the neuromuscular junction. LRP4 also functions as an inhibitor of Wnt/beta-catenin signaling. The identified mutations in LRP4 are located at the edge of its 3rd beta-propeller domain and decrease binding affinity of LRP4 for both MuSK and agrin. Mutations in the LRP4 3rd beta-propeller domain were previously reported to impair Wnt signaling and cause bone diseases including Cenani-Lenz syndactyly syndrome and sclerosteosis-2. By analyzing naturally occurring and artificially introduced mutations in the LRP4 3rd beta-propeller domain, we show that the edge of the domain regulates the MuSK signaling whereas its central cavity governs Wnt signaling. We conclude that LRP4 is a new CMS disease gene and that the 3rd beta propeller domain of LRP4 mediates the two signaling pathways in a position-specific manner.

Indexed as

AdolescentAgrinAnimalsBase Sequencebeta CateninCell LineChlorocebus aethiopsCholinergic AgonistsCholinesterase InhibitorsCOS CellsEdrophoniumEnzyme ActivationFemaleHEK293 CellsHumansLDL-Receptor Related ProteinsAgrinbeta CateninCholinergic AgonistsCholinesterase InhibitorsDOK7 protein, humanEdrophoniumLDL-Receptor Related ProteinsLRP4 protein, humanMuscle ProteinsMUSK protein, humanperipheral membrane protein 43KPyridostigmine BromideReceptor Protein-Tyrosine KinasesReceptors, CholinergicWnt Proteins

Identifiers

PMID24234652
PMCPMC3943522
OpenAlexW2156555464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.